|
1
|
Lok AS, Liang RH, Chiu EK, Wong KL, Chan
TK and Todd D: Reactivation of hepatitis B virus replication in
patients receiving cytotoxic therapy. Report of a prospective
study. Gastroenterology. 100:182–188. 1991.PubMed/NCBI
|
|
2
|
Yeo W, Chan PK, Zhong S, Ho WM, Steinberg
JL, Tam JS, Hui P, Leung NW, Zee B and Johnson PJ: Frequency of
hepatitis B virus reactivation in cancer patients undergoing
cytotoxic chemotherapy: A prospective study of 626 patients with
identification of risk factors. J Med Virol. 62:299–307. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yeo W and Johnson PJ: Diagnosis,
prevention and management of hepatitis B virus reactivation during
anticancer therapy. Hepatology. 43:209–220. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Loomba R, Rowley A, Wesley R, Liang TJ,
Hoofnagle JH, Pucino F and Csako G: Systematic review: The effect
of preventive lamivudine on hepatitis B reactivation during
chemotherapy. Ann Intern Med. 148:519–528. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hoofnagle JH: Reactivation of hepatitis B.
Hepatology. 49(Suppl 5): S156–S165. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hwang JP and Lok AS: Management of
patients with hepatitis B who require immunosuppressive therapy.
Nat Rev Gastroenterol Hepatol. 11:209–219. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yeo W, Chan PK, Hui P, Ho WM, Lam KC, Kwan
WH, Zhong S and Johnson PJ: Hepatitis B virus reactivation in
breast cancer patients receiving cytotoxic chemotherapy: A
prospective study. J Med Virol. 70:553–561. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yeo W, Zee B, Zhong S, Chan PK, Wong WL,
Ho WM, Lam KC and Johnson PJ: Comprehensive analysis of risk
factors associating with hepatitis B virus (HBV) reactivation in
cancer patients undergoing cytotoxic chemotherapy. Br J Cancer.
90:1306–1311. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cheng AL, Hsiung CA, Su IJ, Chen PJ, Chang
MC, Tsao CJ, Kao WY, Uen WC, Hsu CH, Tien HF, et al: Steroid-free
chemotherapy decreases risk of hepatitis B virus (HBV) reactivation
in HBV-carriers with lymphoma. Hepatology. 37:1320–1328. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yeo W, Chan TC, Leung NM, Lam WY, Mo FK,
Chu MT, Chan HL, Hui EP, Lei KI, Mok TS and Chan PK: Hepatitis B
virus reactivation in lymphoma patients with prior resolved
hepatitis B undergoing anticancer therapy with or without
rituximab. J Clin Oncol. 27:605–611. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lau GK, Leung YH, Fong DY, Au WY, Kwong
YL, Lie A, Hou JL, Wen YM, Nanj A and Liang R: High hepatitis B
virus (HBV) DNA viral load as the most important risk factor for
HBV reactivation in patients positive for HBV surface antigen
undergoing autologous hematopoietic cell transplantation. Blood.
99:2324–2330. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ohishi W and Chayama K: Prevention of
hepatitis B virus reactivation in immunosuppressive therapy or
chemotherapy. Clin Exp Nephrol. 15:634–640. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hui CK, Cheung WW, Zhang HY, Au WY, Yueng
YH, Leung AY, Leung N, Luk JM, Lie AK, Kwong YL, et al: Kinetics
and risk of de novo hepatitis B infection in HBsAg-negative
patients undergoing cytotoxic chemotherapy. Gastroenterology.
131:59–68. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ferraro D, Pizzillo P, Di Marco V,
Vultaggio A, Iannitto E, Venezia G, Craxi A and Di Stefano R:
Evaluating the risk of hepatitis B reactivation in patients with
haematological malignancies: Is the serum hepatitis B virus profile
reliable? Liver Int. 29:1171–1177. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lau GK, He ML, Fong DY, Bartholomeusz A,
Au WY, Lie AK, Locarnini S and Liang R: Preemptive use of
lamivudine reduces hepatitis B exacerbation after allogeneic
hematopoietic cell transplantation. Hepatology. 36:702–709. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY,
Lai LS, Cheung M, Zhang HY, Lie A, Ngan R and Liang R: Early is
superior to deferred preemptive lamivudine therapy for hepatitis B
patients undergoing chemotherapy. Gastroenterology. 125:1742–1749.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rossi G, Pelizzari A, Motta M and Puoti M:
Primary prophylaxis with lamivudine of hepatitis B virus
reactivation in chronic HBsAg carriers with lymphoid malignancies
treated with chemotherapy. Br J Haematol. 115:58–62. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chan TM, Fang GX, Tang CS, Cheng IK, Lai
KN and Ho SK: Preemptive lamivudine therapy based on HBV DNA level
in HBsAg-positive kidney allograft recipients. Hepatology.
36:1246–1252. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang
MC, Lin SF, Lin TH, Hsiao HH, Young JH, Chang MC, et al: A revisit
of prophylactic lamivudine for chemotherapy-associated hepatitis B
reactivation in non-Hodgkin's lymphoma: A randomized trial.
Hepatology. 47:844–853. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lok AS and McMahon B: AASLD practice
guidelines chronic hepatitis B: Update 2009. Hepatology. 50:1–36.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lou SC, Pearce SK, Lukaszewska TX, Taylor
RE, Williams GT and Leary TP: An improved Abbott ARCHITECT assay
for the detection of hepatitis B virus surface antigen (HBsAg). J
Clin Virol. 51:59–63. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chevaliez S, Bouvier-Alias M, Laperche S,
Hézode C and Pawlotsky JM: Performance of version 2.0 of the Cobas
AmpliPrep/Cobas TaqMan real-time PCR assay for hepatitis B virus
DNA quantification. J Clin Microbiol. 48:3641–3647. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tur-Kaspa R, Burk RD, Shaul Y and Shafritz
DA: Hepatitis B virus DNA contains a glucocorticoid-responsive
element. Proc Natl Acad Sci USA. 83:1627–1631. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yun J, Kim JH, Kang ES, Gwak GY, Choi MS,
Lee JE, Nam SJ, Yang JH, Park YH, Ahn JS and Im YH: Prophylactic
use of lamivudine for hepatitis B exacerbation in post-operative
breast cancer patients receiving anthracycline-based adjuvant
chemotherapy. Br J Cancer. 104:559–563. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yeo W and Chan HL: Hepatitis B virus
reactivation associated with anti-neoplastic therapy. J
Gastroenterol Hepatol. 28:31–37. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hsu CH, Hsu HC, Chen HL, Gao M, Yeh PY,
Chen PJ and Cheng AL: Doxorubicin activates hepatitis B virus (HBV)
replication in HBV-harboring hepatoblastoma cells. A possible novel
mechanism of HBV reactivation in HBV carriers receiving systemic
chemotherapy. Anticancer Res. 24:3035–3040. 2004.PubMed/NCBI
|
|
27
|
Weinbaum CM, Williams I, Mast EE, Wang SA,
Finelli L, Wasley A, Neitzel SM and Ward JW: Centers for Disease
Control and Prevention (CDC): Recommendations for identification
and public health management of persons with chronic hepatitis B
virus infection. MMWR Recomm Rep. 57:1–20. 2008.PubMed/NCBI
|
|
28
|
European Association For The Study Of The
Liver: EASL clinical practice guidelines: Management of chronic
hepatitis B virus infection. J Hepatol. 57:167–185. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liaw YF, Kao JH, Piratvisuth T, Chan HL,
Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH, et al:
Asian-Pacific consensus statement on the management of chronic
hepatitis B: A 2012 update. Hepatol Int. 6:531–561. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Vassilopoulos D, Apostolopoulou A,
Hadziyannis E, Papatheodoridis GV, Manolakopoulos S, Koskinas J,
Manesis EK and Archimandritis AI: Long-term safety of anti-TNF
treatment in patients with rheumatic diseases and chronic or
resolved hepatitis B virus infection. Ann Rheum Dis. 69:1352–1355.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Marcellin P, Gane E, Buti M, Afdhal N,
Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF,
Aguilar Schall R, et al: Regression of cirrhosis during treatment
with tenofovir disoproxil fumarate for chronic hepatitis B: A
5-year open-label follow-up study. Lancet. 381:468–475. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tenney DJ, Rose RE, Baldick CJ,
Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, Xu D, Yang J,
Wilber RB and Colonno RJ: Long-term monitoring shows hepatitis B
virus resistance to entecavir in nucleoside-naïve patients is rare
through 5 years of therapy. Hepatology. 49:1503–1514. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li HR, Huang JJ, Guo HQ, Zhang X, Xie Y,
Zhu HL, Zhai LZ, Pu XX, Huang Y, Guo CC and Lin TY: Comparison of
entecavir and lamivudine in preventing hepatitis B reactivation in
lymphoma patients during chemotherapy. J Viral Hepat. 18:877–883.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hui CK, Cheung WW, Au WY, Lie AK, Zhang
HY, Yueng YH, Wong BC, Leung N, Kwong YL, Liang R and Lau GK:
Hepatitis B reactivation after withdrawal of pre-emptive lamivudine
in patients with haematological malignancy on completion of
cytotoxic chemotherapy. Gut. 54:1597–1603. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Blumberg BS, Sutnick AI and London WT:
Hepatitis and leukemia: Their relation to Australia antigen. Bull N
Y Acad Med. 44:1566–1586. 1968.PubMed/NCBI
|
|
36
|
Chan HL, Thompson A, Martinot-Peignoux M,
Piratvisuth T, Cornberg M, Brunetto MR, Tillmann HL, Kao JH, Jia
JD, Wedemeyer H, et al: Hepatitis B surface antigen quantification:
Why and how to use it in 2011 - a core group report. J Hepatol.
55:1121–1131. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nguyen T, Desmond P and Locarnini S: The
role of quantitative hepatitis B serology in the natural history
and management of chronic hepatitis B. Hepatol Int. 3(Suppl 1):
S5–S15. 2009. View Article : Google Scholar
|
|
38
|
Chen CH, Lee CM, Wang JH, Tung HD, Hung CH
and Lu SN: Correlation of quantitative assay of hepatitis B surface
antigen and HBV DNA levels in asymptomatic hepatitis B virus
carriers. Eur J Gastroenterol Hepatol. 16:1213–1218. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chan HL, Wong VW, Tse AM, Tse CH, Chim AM,
Chan HY, Wong GL and Sung JJ: Serum hepatitis B surface antigen
quantitation can reflect hepatitis B virus in the liver and predict
treatment response. Clin Gastroenterol Hepatol. 5:1462–1468. 2007.
View Article : Google Scholar : PubMed/NCBI
|
